Sugi Predict

Sugi Predict / Compounds / SCHEMBL24717559

SCHEMBL24717559

SCHEMBL24717559

Cc1ccc(Br)c2c(C#N)c(NC(=O)OC(C)(C)C)sc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.36
▸ NPC1 O15118 4/20 0.36
▸ RAB9A P51151 4/20 0.36
▸ LCK P06239 5/20 0.35
▸ MAPK10 P53779 1/20 0.34
▸ MAPT P10636 4/20 0.33
▸ POLB P06746 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CTDSP1 Q9GZU7 1/20 0.33
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23498289 0.88 MEN1 (0.36) ALDH1A1NPC1RAB9AMAPK10MAPT
SCHEMBL29812974 0.88 MEN1 (0.36) ALDH1A1NPC1RAB9AMAPK10MAPT
SCHEMBL25643117 0.87 ALDH1A1 (0.38) ALDH1A1NPC1MAPTPOLBSMN1; SMN2
SCHEMBL24718536 0.85 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL23496898 0.81 LCK (0.39) ALDH1A1NPC1RAB9ALCKMAPK10
SCHEMBL29813129 0.81 LCK (0.39) ALDH1A1NPC1RAB9ALCKMAPK10
SCHEMBL30014245 0.80 ALDH1A1 (0.47) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL25639711 0.79 ATR (0.37) ALDH1A1LCKMAPTSMN1; SMN2MEN1
SCHEMBL30776330 0.78 LCK (0.37) ALDH1A1NPC1RAB9ALCKMAPT
SCHEMBL26530970 0.78 LCK (0.37) ALDH1A1NPC1RAB9ALCKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228511-A1 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS ELI LILLY AND COMPANY 2024-07-11 — — US disclosed
US-20240228511-A1 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS ELI LILLY AND COMPANY 2024-07-11 — — US disclosed
US-20240228511-A1 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS ELI LILLY AND COMPANY 2024-07-11 — — US disclosed
CN-117500799-A Substituted fused azines as KRAS G12D inhibitors 伊莱利利公司 2024-02-02 — — CN disclosed
WO-2022261154-A1 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS ELI LILLY AND COMPANY (US) 2022-12-15 — — WO disclosed
WO-2022261154-A1 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS ELI LILLY AND COMPANY (US) 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228511-A1 SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS KRAS, NRAS, TP53 ALDH1A1 3265/4885NPC1 2826/4885RAB9A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.